06.26.18
ProBioGen AG and Nouscom AG have signed a license agreement giving Nouscom access to ProBioGen’s production platform based on the AGE1. CR duck retina Cell line for production of its viral vectored vaccines.
Dr. Volker Sandig, ProBioGen’s chief scientific officer, said, “We have developed the AGE1.CR® designer cell line, the chemically defined media and the process over many years, aiming to overcome challenges in the production of highly attenuated poxvirus vectors. We are very pleased to see a strong industry demand for our platform and are convinced that Nouscom´s highly innovative Vaccine approach will greatly benefit from it.”
Nouscom’s chief technology officer, Dr. Stefano Colloca added, “We are very pleased with this new partnership with ProBioGen which allows us to utilize a scalable GMP manufacturing process for production of our viral vectored vaccines. This is an important milestone in our journey towards becoming a clinical stage company.”
Dr. Volker Sandig, ProBioGen’s chief scientific officer, said, “We have developed the AGE1.CR® designer cell line, the chemically defined media and the process over many years, aiming to overcome challenges in the production of highly attenuated poxvirus vectors. We are very pleased to see a strong industry demand for our platform and are convinced that Nouscom´s highly innovative Vaccine approach will greatly benefit from it.”
Nouscom’s chief technology officer, Dr. Stefano Colloca added, “We are very pleased with this new partnership with ProBioGen which allows us to utilize a scalable GMP manufacturing process for production of our viral vectored vaccines. This is an important milestone in our journey towards becoming a clinical stage company.”
